Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers.

McCann SE, Edge SB, Hicks DG, Thompson LU, Morrison CD, Fetterly G, Andrews C, Clark K, Wilton J, Kulkarni S.

Nutr Cancer. 2014;66(4):566-75. doi: 10.1080/01635581.2014.894097. Epub 2014 Mar 26.

2.

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M.

J Clin Oncol. 2012 Aug 20;30(24):2977-80. doi: 10.1200/JCO.2012.42.0273. Epub 2012 Jul 16.

PMID:
22802308
3.

Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.

Moy I, Lin Z, Rademaker AW, Reierstad S, Khan SA, Bulun SE.

PLoS One. 2013 Nov 6;8(11):e77543. doi: 10.1371/journal.pone.0077543. eCollection 2013.

4.

Aromatase inhibitors and calcium absorption in early stage breast cancer.

Tevaarwerk A, Burkard ME, Wisinski KB, Shafer MM, Davis LA, Gogineni J, Crone E, Hansen KE.

Breast Cancer Res Treat. 2012 Jul;134(1):245-51. doi: 10.1007/s10549-012-1982-z. Epub 2012 Feb 18.

5.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Hole S, Pedersen AM, Hansen SK, Lundqvist J, Yde CW, Lykkesfeldt AE.

Int J Oncol. 2015 Apr;46(4):1481-90. doi: 10.3892/ijo.2015.2850. Epub 2015 Jan 26.

6.

miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.

Bacci M, Giannoni E, Fearns A, Ribas R, Gao Q, Taddei ML, Pintus G, Dowsett M, Isacke CM, Martin LA, Chiarugi P, Morandi A.

Cancer Res. 2016 Mar 15;76(6):1615-26. doi: 10.1158/0008-5472.CAN-15-2038. Epub 2016 Jan 21.

7.

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.

Thomsen KG, Lyng MB, Elias D, Vever H, Knoop AS, Lykkesfeldt AE, Lænkholm AV, Ditzel HJ.

Breast Cancer Res Treat. 2015 Dec;154(3):483-94. doi: 10.1007/s10549-015-3644-4. Epub 2015 Nov 19.

PMID:
26585578
8.

Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.

Hubalek M, Oberguggenberger A, Beer B, Meraner V, Sztankay M, Oberacher H, Schubert B, Wildt L, Seeber B, Giesinger J, Kemmler G, Holzner B, Sperner-Unterweger B.

Clin Breast Cancer. 2014 Aug;14(4):291-6. doi: 10.1016/j.clbc.2013.12.008. Epub 2013 Dec 27.

PMID:
24468298
9.

Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.

Motomura K, Ishitobi M, Komoike Y, Koyama H, Nagase H, Inaji H, Noguchi S.

Oncology. 2010;79(1-2):55-61. doi: 10.1159/000319540. Epub 2010 Nov 11.

PMID:
21071990
10.
11.

Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.

Smollich M, Götte M, Fischgräbe J, Radke I, Kiesel L, Wülfing P.

Anticancer Res. 2009 Jun;29(6):2167-71.

12.

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.

Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA.

Int J Cancer. 2013 Oct 1;133(7):1589-602. doi: 10.1002/ijc.28182. Epub 2013 May 2.

13.

AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.

O'Hara J, Vareslija D, McBryan J, Bane F, Tibbitts P, Byrne C, Conroy RM, Hao Y, Gaora PÓ, Hill AD, McIlroy M, Young LS.

Clin Cancer Res. 2012 Jun 15;18(12):3305-15. doi: 10.1158/1078-0432.CCR-11-3300. Epub 2012 May 1.

14.

Flaxseed and its lignan and oil components: can they play a role in reducing the risk of and improving the treatment of breast cancer?

Mason JK, Thompson LU.

Appl Physiol Nutr Metab. 2014 Jun;39(6):663-78. doi: 10.1139/apnm-2013-0420. Epub 2013 Dec 23. Review.

PMID:
24869971
15.

AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.

Wong C, Wang X, Smith D, Reddy K, Chen S.

Breast Cancer Res Treat. 2012 Jul;134(2):671-81. doi: 10.1007/s10549-012-2105-6. Epub 2012 Jun 16.

16.

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.

Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4.

17.

Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.

Nair HB, Kirma NB, Ganapathy M, Vadlamudi RK, Tekmal RR.

Steroids. 2011 Jul;76(8):792-6. doi: 10.1016/j.steroids.2011.02.038. Epub 2011 Apr 6.

PMID:
21477609
18.

Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.

Hanamura T, Niwa T, Nishikawa S, Konno H, Gohno T, Tazawa C, Kobayashi Y, Kurosumi M, Takei H, Yamaguchi Y, Ito K, Hayashi S.

Breast Cancer Res Treat. 2013 Jun;139(3):731-40. doi: 10.1007/s10549-013-2595-x. Epub 2013 Jun 19.

PMID:
23780684
19.

Obesity and endocrine therapy: host factors and breast cancer outcome.

Goodwin PJ.

Breast. 2013 Aug;22 Suppl 2:S44-7. doi: 10.1016/j.breast.2013.07.008. Review.

PMID:
24074791
20.

Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.

Dalenc F, Iuliano L, Filleron T, Zerbinati C, Voisin M, Arellano C, Chatelut E, Marquet P, Samadi M, Roché H, Poirot M, Silvente-Poirot S.

J Steroid Biochem Mol Biol. 2017 May;169:210-218. doi: 10.1016/j.jsbmb.2016.06.010. Epub 2016 Jun 22.

PMID:
27343991

Supplemental Content

Support Center